Cytokeratin 34betaE12

Cytokeratin 34betaE12 (CK34βE12) is a special protein that belongs to a family of proteins called cytokeratins. Cytokeratins form part of the supportive framework inside specific cells known as epithelial cells, which cover surfaces and line organs throughout the body. Specifically, CK34βE12 is a “high molecular weight” cytokeratin, meaning it is larger and helps maintain the structural integrity of complex epithelial tissues. It is particularly useful in pathology because it helps pathologists identify and distinguish specific types of epithelial cells in tissue samples.

What types of normal cells and tissues express CK34βE12?

CK34βE12 is normally found in specific epithelial tissues that have multiple layers of cells, called stratified epithelia, as well as in the basal cells of certain glands. Examples include:

• Skin: CK34βE12 is present in the basal (bottom) layers of the skin.

• Prostate gland: The basal cells of the prostate gland express CK34βE12.

• Breast tissue: CK34βE12 appears in the cells lining ducts within breast tissue.

• Urinary bladder and urethra: CK34βE12 is expressed in the epithelial lining of the bladder and urinary tract.

• Upper respiratory tract: The lining of the nasal passages and throat commonly expresses CK34βE12.

How do pathologists test for CK34βE12?

Pathologists test for CK34βE12 using a method called immunohistochemistry (IHC). This technique involves applying antibodies designed specifically to bind to CK34βE12 in a small tissue sample. If CK34βE12 is present, these antibodies attach to it and cause a visible colour change under the microscope. Pathologists then carefully examine this staining to determine if CK34βE12 is present or absent, and how strongly it is expressed. A positive result means that the cells express CK34βE12, while a negative result means they do not.

What types of tumours express CK34βE12?

CK34βE12 is helpful to pathologists because certain tumours show unique patterns of expression. Tumours that commonly express CK34βE12 include:

• Prostate tumours: CK34βE12 helps distinguish benign (noncancerous) prostate conditions from prostate cancer. Benign prostate glands typically show clear CK34βE12 staining in their basal cell layer. In contrast, typical prostate cancers lose this basal cell layer and thus are negative for CK34βE12.

• Breast tumours: Usual ductal hyperplasia (a benign condition) and lobular carcinoma in situ (LCIS) often strongly express CK34βE12. In contrast, atypical ductal hyperplasia and ductal carcinoma in situ (DCIS), which have the potential to progress to invasive breast cancer, typically show weak or negative staining.

• Bladder and urinary tract tumours: CK34βE12 is positive in invasive urothelial carcinoma, a type of bladder cancer. It also helps distinguish between carcinoma in situ (which stains strongly) and benign or precancerous changes (which show limited basal staining).

• Lung and skin tumours: Squamous cell carcinomas, including those of the lung and skin, often strongly express CK34βE12, helping pathologists distinguish them from other types of tumours.

• Other tumours: Certain rare tumours, such as adenoid cystic carcinoma of the prostate, basaloid carcinomas, and specific ovarian and endometrial tumours, may also exhibit CK34βE12 expression.

Why is CK34βE12 important in a pathology report?

Testing for CK34βE12 helps pathologists accurately diagnose different types of tumours, distinguish between benign and malignant conditions, and provide valuable information about tumour characteristics and potential treatment options.

In prostate biopsies, for example, CK34βE12 staining can determine whether suspicious glands represent prostate cancer or a benign condition. A special combination of CK34βE12, p63, and AMACR antibodies (known as the “triple cocktail”) provides even greater accuracy for diagnosing prostate cancer.

Additionally, the presence or absence of CK34βE12 can influence treatment choices and prognosis. For instance, certain breast tumours or bladder cancers with specific CK34βE12 staining patterns may have different behaviours and thus require various treatments.

By evaluating CK34βE12 expression, pathologists contribute critical information to your healthcare team, helping them select the most effective treatment tailored to your condition.